These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 33780862)

  • 1. Crystal structures of two inhibitors in complex with histone lysine demethylase 4D (KDM4D) provide new insights for rational drug design.
    Wang T; Liu Y; Zhang H; Fang Z; Zhang R; Zhang W; Fan Y; Xiang R
    Biochem Biophys Res Commun; 2021 May; 554():71-75. PubMed ID: 33780862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of pyrazolo[1,5-a]pyrimidine-3-carbonitrile derivatives as a new class of histone lysine demethylase 4D (KDM4D) inhibitors.
    Fang Z; Wang TQ; Li H; Zhang G; Wu XA; Yang L; Peng YL; Zou J; Li LL; Xiang R; Yang SY
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3201-3204. PubMed ID: 28539219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a potent and selective inhibitor of histone lysine demethylase KDM4D.
    Fang Z; Liu Y; Zhang R; Chen Q; Wang T; Yang W; Fan Y; Yu C; Xiang R; Yang S
    Eur J Med Chem; 2021 Nov; 223():113662. PubMed ID: 34237635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitor scaffold for the histone lysine demethylase KDM4C (JMJD2C).
    Leurs U; Clausen RP; Kristensen JL; Lohse B
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5811-3. PubMed ID: 22917519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA-dependent chromatin localization of KDM4D lysine demethylase promotes H3K9me3 demethylation.
    Zoabi M; Nadar-Ponniah PT; Khoury-Haddad H; Usaj M; Budowski-Tal I; Haran T; Henn A; Mandel-Gutfreund Y; Ayoub N
    Nucleic Acids Res; 2014 Dec; 42(21):13026-38. PubMed ID: 25378304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substituted 2-(2-aminopyrimidin-4-yl)pyridine-4-carboxylates as potent inhibitors of JumonjiC domain-containing histone demethylases.
    Roatsch M; Robaa D; Pippel M; Nettleship JE; Reddivari Y; Bird LE; Hoffmann I; Franz H; Owens RJ; Schüle R; Flaig R; Sippl W; Jung M
    Future Med Chem; 2016 Sep; 8(13):1553-71. PubMed ID: 26971619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based mapping of the histone-binding pocket of KDM4D using functionalized tetrazole and pyridine core compounds.
    Małecki PH; Fassauer GM; Rüger N; Schulig L; Link A; Krylova O; Heinemann U; Weiss MS
    Eur J Med Chem; 2024 Oct; 276():116642. PubMed ID: 38981336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives.
    Westaway SM; Preston AG; Barker MD; Brown F; Brown JA; Campbell M; Chung CW; Drewes G; Eagle R; Garton N; Gordon L; Haslam C; Hayhow TG; Humphreys PG; Joberty G; Katso R; Kruidenier L; Leveridge M; Pemberton M; Rioja I; Seal GA; Shipley T; Singh O; Suckling CJ; Taylor J; Thomas P; Wilson DM; Lee K; Prinjha RK
    J Med Chem; 2016 Feb; 59(4):1370-87. PubMed ID: 26771203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-Based Screening of Tetrazolylhydrazide Inhibitors versus KDM4 Histone Demethylases.
    Małecki PH; Rüger N; Roatsch M; Krylova O; Link A; Jung M; Heinemann U; Weiss MS
    ChemMedChem; 2019 Nov; 14(21):1828-1839. PubMed ID: 31475772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The histone demethylase KDM4D promotes hepatic fibrogenesis by modulating Toll-like receptor 4 signaling pathway.
    Dong F; Jiang S; Li J; Wang Y; Zhu L; Huang Y; Jiang X; Hu X; Zhou Q; Zhang Z; Bao Z
    EBioMedicine; 2019 Jan; 39():472-483. PubMed ID: 30527625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The emerging role of lysine demethylases in DNA damage response: dissecting the recruitment mode of KDM4D/JMJD2D to DNA damage sites.
    Khoury-Haddad H; Nadar-Ponniah PT; Awwad S; Ayoub N
    Cell Cycle; 2015; 14(7):950-8. PubMed ID: 25714495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate Derivatives.
    Westaway SM; Preston AG; Barker MD; Brown F; Brown JA; Campbell M; Chung CW; Diallo H; Douault C; Drewes G; Eagle R; Gordon L; Haslam C; Hayhow TG; Humphreys PG; Joberty G; Katso R; Kruidenier L; Leveridge M; Liddle J; Mosley J; Muelbaier M; Randle R; Rioja I; Rueger A; Seal GA; Sheppard RJ; Singh O; Taylor J; Thomas P; Thomson D; Wilson DM; Lee K; Prinjha RK
    J Med Chem; 2016 Feb; 59(4):1357-69. PubMed ID: 26771107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KDM4B as a target for prostate cancer: structural analysis and selective inhibition by a novel inhibitor.
    Chu CH; Wang LY; Hsu KC; Chen CC; Cheng HH; Wang SM; Wu CM; Chen TJ; Li LT; Liu R; Hung CL; Yang JM; Kung HJ; Wang WC
    J Med Chem; 2014 Jul; 57(14):5975-85. PubMed ID: 24971742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of pyrazole derivatives as cellular active inhibitors of histone lysine specific demethylase 5B (KDM5B/JARID1B).
    Zhao B; Liang Q; Ren H; Zhang X; Wu Y; Zhang K; Ma LY; Zheng YC; Liu HM
    Eur J Med Chem; 2020 Apr; 192():112161. PubMed ID: 32155529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays.
    Le Bihan YV; Lanigan RM; Atrash B; McLaughlin MG; Velupillai S; Malcolm AG; England KS; Ruda GF; Mok NY; Tumber A; Tomlin K; Saville H; Shehu E; McAndrew C; Carmichael L; Bennett JM; Jeganathan F; Eve P; Donovan A; Hayes A; Wood F; Raynaud FI; Fedorov O; Brennan PE; Burke R; van Montfort RLM; Rossanese OW; Blagg J; Bavetsias V
    Eur J Med Chem; 2019 Sep; 177():316-337. PubMed ID: 31158747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone demethylase KDM4D cooperates with NFIB and MLL1 complex to regulate adipogenic differentiation of C3H10T1/2 mesenchymal stem cells.
    Choi JH; Lee H
    Sci Rep; 2020 Feb; 10(1):3050. PubMed ID: 32080306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural definitions of Jumonji family demethylase selectivity.
    Pilka ES; James T; Lisztwan JH
    Drug Discov Today; 2015 Jun; 20(6):743-9. PubMed ID: 25555749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural analysis of human KDM5B guides histone demethylase inhibitor development.
    Johansson C; Velupillai S; Tumber A; Szykowska A; Hookway ES; Nowak RP; Strain-Damerell C; Gileadi C; Philpott M; Burgess-Brown N; Wu N; Kopec J; Nuzzi A; Steuber H; Egner U; Badock V; Munro S; LaThangue NB; Westaway S; Brown J; Athanasou N; Prinjha R; Brennan PE; Oppermann U
    Nat Chem Biol; 2016 Jul; 12(7):539-45. PubMed ID: 27214403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based design and discovery of potent and selective KDM5 inhibitors.
    Nie Z; Shi L; Lai C; O'Connell SM; Xu J; Stansfield RK; Hosfield DJ; Veal JM; Stafford JA
    Bioorg Med Chem Lett; 2018 May; 28(9):1490-1494. PubMed ID: 29627262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Control of enhancer and promoter activation in the type I interferon response by the histone demethylase Kdm4d/JMJD2d.
    Chandwani R; Fang TC; Dewell S; Tarakhovsky A
    Front Immunol; 2023; 14():1146699. PubMed ID: 37275914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.